US OptionsDetailed Quotes
PTN240517C5000
- 0.08
- 0.000.00%
15min DelayClose May 3 13:07 ET
0.00High0.00Low
0.00Open0.08Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover8270.89%IV149.02%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.08Time Value100Contract SizeAmericanOptions Type0.1507Delta0.1746Gamma25.50Leverage Ratio-6.4065Theta0.0000Rho3.84Eff Leverage0.0000Vega
Palatin Technologies Stock Discussion
Sign in to post a comment
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
5
1
The co-administration of bremelanotide with tirzepatide represents a novel therapeutic strategy for the treatment of obesity.
Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently made a significant stride in the treatment of obesity by gaining FDA clearance for its Investigational New Drug (IND) application. This clearance allows Palatin to proceed with a Phase 2 clinical study e...
Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently made a significant stride in the treatment of obesity by gaining FDA clearance for its Investigational New Drug (IND) application. This clearance allows Palatin to proceed with a Phase 2 clinical study e...
$Palatin Technologies(PTN.US$ Reuters· 1 min ago
Palatin Announces FDA Clearance of Ind Application for the Co-Administration of Bremelanotide With Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Announces FDA Clearance of Ind Application for the Co-Administration of Bremelanotide With Tirzepatide (GLP-1) for the Treatment of Obesity
1
$Palatin Technologies(PTN.US$
NEWS
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
NEWS
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
1
$Palatin Technologies(PTN.US$
NEWS
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
NEWS
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
1
1
Breakthrough in Dry Eye Disease Treatment: Insights from PL9643 MELODY-1 Phase 3 Trial.
In a significant development for millions suffering from Dry Eye Disease (DED), Palatin Technologies, Inc. recently unveiled the results of their Phase 3 PL9643 MELODY-1 clinical trial at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) conference in 2024. The findings mark a promising advancement...
In a significant development for millions suffering from Dry Eye Disease (DED), Palatin Technologies, Inc. recently unveiled the results of their Phase 3 PL9643 MELODY-1 clinical trial at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) conference in 2024. The findings mark a promising advancement...
1
$Nasdaq Composite Index(.IXIC.US$ $NASDAQ 100 Index(.NDX.US$
$Palatin Technologies(PTN.US$ this company is huge opportunity it has massive funding with 6B USD it’s go to the top 100% sure.
my advice is buy
$Palatin Technologies(PTN.US$ this company is huge opportunity it has massive funding with 6B USD it’s go to the top 100% sure.
my advice is buy
2
3
$Palatin Technologies(PTN.US$
the $Palatin Technologies(PTN.US$ will go to the point because it has 6B USD funding
now buy this is moment
the $Palatin Technologies(PTN.US$ will go to the point because it has 6B USD funding
now buy this is moment
1
$Palatin Technologies(PTN.US$
Palatin Technologies, Inc. announced positive Phase 3 trial results for PL9643, a potential treatment for dry eye disease (DED), presented by Dr. Eric Donnenfeld at the American Society of Cataract and Refractive Surgery Conference.
The study showed statistically significant improvement in pain and multiple seco...
Palatin Technologies, Inc. announced positive Phase 3 trial results for PL9643, a potential treatment for dry eye disease (DED), presented by Dr. Eric Donnenfeld at the American Society of Cataract and Refractive Surgery Conference.
The study showed statistically significant improvement in pain and multiple seco...
1
No comment yet
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long